# Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.

> **NCT02455687** · PHASE3 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 240 (estimated)

## Conditions studied

- Bronchial Asthma

## Interventions

- **DRUG:** Hi-dose iv MgSO4
- **DRUG:** Nebulized budesonide
- **DRUG:** Std-dose iv MgSO4
- **DRUG:** Nebulized normal saline

## Key facts

- **NCT ID:** NCT02455687
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2024-12
- **Final completion:** 2025-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02455687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02455687, "Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02455687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*